Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 4Other hematologic neoplasm 1Myeloid 1Gynecologic 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1Anemia 1

Interventions

luspatercept 4Biopsy 4Lenalidomide 3Epoetin Alfa 3Cyclophosphamide 3Busulfan 3ruxolitinib 2fludarabine 2Filgrastim 2Cyclosporine 2Antilymphocyte Serum 2AP 1903 reagent 2ACE-011 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1vactosertib 1trametinib 1thymoglobulin 1siltuximab 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Blood Transfusion × Myeloid × Clear all
NCT03086252 2018-07-26

Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study

Emory University

Phase NA Withdrawn
Classical hematologyMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Anemia, Aplastic, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡